Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Williams, Sarah K ^a   Maier, Olaf ^b   Fischer, Roman ^b   Fairless, Richard ^a   Hochmeister, Sonja ^c   Stojic, Aleksandar ^a   Pick, Lara ^d   Haar, Doreen ^d   Musiol, Sylvia ^d   Storch, Maria K ^c   Pfizenmaier, Klaus ^b   Diem, Ricarda ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF STUTTGART   (Germany)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HM 1097; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG SELECTIVITY; DRUG TARGETING; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GENE EXPRESSION; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; MULTIPLE SCLEROSIS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II;

EID: 84896507711     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090117     Document Type: Article

References (48)

1. Davie CA, Barker GJ, Webb S, Tofts PS, Thompson AJ, et al. (1995) Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 118: 1583-1592. (Pubitemid 26011926)
2. Losseff NA, Wang L, Lai HM, Yoo DS, Gawne-Cain ML, et al. (1996) Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 119: 2009-2019.
3. Trapp BD, Ransohoff R, Rudick R (1999) Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 12: 295-302. (Pubitemid 29378163)
4. Wajant H, Pfizenmaier K, Scheurich P (2003) Tumor necrosis factor signaling. Cell Death Diff 10: 45-65. (Pubitemid 36511832)
5. Kontermann RE, Scheurich P, Pfizenmaier K (2009) Antagonists of TNF action: clinical experience and new developments. Expert Opin. Drug Discov 4: 279-292.
6. Hauser SL, Doolittle TH, Lincoln R, Brown RH, Dinarello CA (1990) Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumour necrosis factor but not interleuin-6. Neurology 40: 1735-1739. (Pubitemid 20383141)
7. Sharief MK, Hentges R (1991) Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. New Engl J Med 325: 467-472.
8. Hofman FM, Hinton DR, Johnson K, Merrill JE (1989) Tumour necrosis factor identified in multiple sclerosis brain. J Exp Med 170: 607-612. (Pubitemid 19204288)
9. Canella B, Raine CS (1995) The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 27: 424-435.
10. Baker D, Butler D, Scallon BJ, O'Neill JK, Turk JL, et al. (1994) Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol 24: 2040-2048.
11. Ruddle NH, Bergman CM, McGrath KM, Lingenheld EG, Grunnet ML, et al. (1990) An antibody to lymphotoxin and tumour necrosis factor prevents transfer of experimental allergic enchephalomyelitis. J Exp Med, 172: 1193-2000.
12. van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, et al. (1996) Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47: 1531-1534. (Pubitemid 26422549)
13. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1999) TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53: 457-465.
14. Sicotte NL, Voskuhl RR (2001) Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 57: 1885-1888. (Pubitemid 33096700)
15. Richez C, Blanco P, Lagueny A, Schaeverbeke T, Dehais J (2005) Neuropathology resembling CIDP in patients receiving tumour necrosis factor-a blockers. Neurology, 64: 1468-1470. (Pubitemid 40570527)
16. Grell M, Douni E, Wajant H, Löhden M, Clauss M, et al. (1995) The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83: 793-802.
17. Akassoglou K, Bauer J, Kassiotis G, Pasparakis M, Lassmann H, et al. (1998) Oligodendrocyte apoptosis and primary demyelination induced by local TNF/ p55TNF receptor signaling in the central nervous system of transgenic mice. Am J Pathol 153: 801-813. (Pubitemid 28419033)
18. McCoy MK, Tansey MG (2008) TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 5: 45.
19. Fontaine V, Mohand-Said S, Hanoteau N, Fuchs C, Pfizenmaier K, et al. (2002) Neurodegenerative and neuroprotective effects of tumor Necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci 22: RC216.
20. Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, et al. (2001) TNFa promotes proliferation of oligodendrocyte progenitors and remyelination. Nature Neurosci 4: 1116-1122. (Pubitemid 34116557)
21. Shibata H, Yoshioka Y, Ohkawa A, Minowa K, Mukai Y, et al. (2008) Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist. J Biol Chem 283: 998-1007.
22. Nomura T, Abe Y, Kamada H, Shibata H, Kayamuro H, et al. (2011) Therapeutic effect of PEGylated TNFR1-selective antagonistic mutant TNF in experimental autoimmune encephalomyelitis mice. J Control Release. 149: 8-14.
23. Brambilla R, Ashbaugh JJ, Magliozzi R, Dellarole A, Karmally S, et al. (2011) Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. Brain 134: 2736-2754.
24. Taoufik E, Tseveleki V, Chu SY, Tselios T, Karin M, et al. (2011) Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-kB. Brain 134: 2722-2735.
25. Wang Y-L, Chou F-C, Chen S-J, Lin A-H, Chang D-M, et al. (2011) Targeting pre-ligand assembly domain of TNFR1 ameliorates autoimmune diseases - An unrevealed role in downregulation of Th17 cells. J Autoimmunity 37: 160-170.
26. Rothe J, Lesslauer W, Lötscher H, Lang Y, Koebel P, et al. (1993) Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364: 798-802. (Pubitemid 23261759)
27. Erickson SL, de Sauvage FJ, Kikly K, Carver-Moore K, Pitts-Meek S, et al. (1994) Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 372: 560-563.
28. Sheehan KC, Pinckard JK, Arthur CD, Dehner LP, Goeddel DV, et al. (1995) Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor recepors: identification of a novel in vivo role for p75. J Exp Med. 181: 607-617.
29. Storch MK, Stefferl A, Brehm U, Weissert R, Wallström E, et al. (1998) Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 8: 681-694. (Pubitemid 28460927)
30. Eugster HP, Frei K, Bachmann R, Bluethmann H, Lassmann H, et al. (1999) Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1. Eur J Immunol 29: 626-632. (Pubitemid 29078524)
31. Suvannavejh GC, Lee HO, Padilla J, Dal Canto MC, Barrett TA, et al. (2000) Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG(35-55)-induced experimental autoimmune encephalomyelitis. Cell Immunol 205: 24-33.
32. Kassiotis G, Kollias G (2001) Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med 193: 427-434. (Pubitemid 32524474)
33. Teuscher C, Bunn JY, Fillmore PD, Butterfield RJ, Zachary JF, et al. (2004) Gender, Age, and Season at Immunization Uniquely Influence the Genetic Control of Susceptibility to Histopathological Lesions and Clinical Signs of Experimental Allergic Encephalomyelitis. Am J Path 165: 1593-1602. (Pubitemid 39435158)
34. Fairless R, Williams SK, Hoffmann DB, Stojic A, Hochmeister S, et al. (2012) Preclinical retinal neurodegeneration in a model of multiple sclerosis. J Neurosci 32: 5585-5597.
35. Marchetti L, Klein M, Schlett K, Pfizenmaier K, Eisel UL (2004) Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinasedependent NF-kappa B pathway. J Biol Chem 279: 32869-32881. (Pubitemid 39014747)
36. Dolga AM, Nijholt IM, Ostroveanu A, Ten Bosch Q, Luiten PG, et al. (2008) Lovastatin induces neuroprotection through tumor necrosis factor receptor 2 signaling pathways. J Alzheimers Dis 13: 111-122. (Pubitemid 352038517)
37. Caminero A, Comabella M, Montalban X (2011) Tumor necrosis factor alpha (TNF-a), anti-TNF-a and demyelination revisited: an ongoing story. J Neuroimmunol. 234: 1-6.
38. Van Hauwermeiren F, Vandenbroucke RE, Libert C (2011) Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1. Cytokine Growth Factor Rev. 22: 311-319.
39. Kitagaki M, Isoda K, Kamada H, Kobayashi T, Tsunoda S, et al. (2012) Novel TNF-a receptor 1 antagonist treatment attenuates arterial inflammation and intimal hyperplasia in mice. J Atheroscler Thromb 19: 36-46.
40. Steed PM, Tansey MG, Zalevsky J, Zhukovsky EA, Desjarlais JR, et al. (2003) Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 301: 1895-1898. (Pubitemid 37221393)
41. De Jager PL, Jia X, Wang J, de Bakker PI, Ottoboni L, et al. (2009) Metaanalysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 41: 776-782.
42. Gregory AP, Dendrou CA, Attfield KE, Haghikia A, Xifara DK, et al. (2012) TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 488: 508-511.
43. Gimenez MA, Sim JE, Russell JH (2004) TNFR1-dependent VCAM-1 expression by astrocytes exposes the CNS to destructive inflammation. J Neuroimmunol 151: 116-125. (Pubitemid 38624406)
44. Körner H, Goodsall AL, Lemckert FA, Scallon BJ, Ghrayeb J, et al. (1995) Unimpaired autoreactive T-cell traffic within the central nervous system during tumor necrosis factor receptor-mediated inhibition of experimental autoimmune encephalomyelitis. PNAS 92: 11066-11070.
45. Körner H, Lemckert FA, Chaudhri G, Etteldorf S, Sedgwick JD (1997) Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system. Eur J Immunol 27: 1973-1981. (Pubitemid 27346013)
46. Fischer R, Maier O, Siegemund M, Wajant H, Scheurich P, et al. (2011) A TNF receptor 2 selective agonist rescues human neurons from oxidative stress-induced cell death. PLoS One 6: e27621.
47. Patel JR, Williams JL, Muccigrosso MM, Liu L, Sun T, et al. (2012) Astrocyte TNFR2 is required for CXCL12-mediated regulation of oligodendrocyte progenitor proliferation and differentiation within the adult CNS. Acta Neuropathol 124: 847-860.
48. Veroni C, Gabriele L, Canini I, Castiello L, Coccia E, et al. (2010) Activation of TNF receptor 2 in microglia promotes induction of anti-inflammatory pathways. Mol Cell Neurosci 45: 234-244.